New study tracks immune reactions to MS shot in 400 patients
NCT ID NCT05925049
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 26 times
Summary
This study looks at how many people with multiple sclerosis (MS) develop antibodies against the drug natalizumab when they receive it as an injection under the skin. Researchers will track about 400 patients from European MS registries, including both those new to the drug and those switching from an IV form. The goal is to better understand immune reactions and safety, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Cambridge, Massachusetts, 02142, United States
Conditions
Explore the condition pages connected to this study.